Advertisement

Clinical Rheumatology

, Volume 36, Issue 12, pp 2637–2644 | Cite as

Asymptomatic hyperuricemia: is it time to intervene?

  • Binoy J. Paul
  • K. Anoopkumar
  • Vinod Krishnan
Review Article

Abstract

Whether to treat hyperuricemia uncomplicated by articular gout, urolithiasis, or uric acid nephropathy is an exercise in clinical judgment and universal agreement is lacking. Patients with coronary artery disease, chronic kidney disease, and early onset hypertension with persistent hyperuricemia are likely to be benefited with urate-lowering therapy. The paradigm of the causative association of hyperuricemia with cardiovascular and chronic kidney diseases seems to have progressed from skepticism to increasing evidence of a true relationship. Although such evidences are mounting, they are not enough to support pharmacotherapy for all patients with asymptomatic hyperuricemia. Further studies are needed to determine which patients are likely to get beneficial effects from pharmacotherapy and the minimum threshold of uric acid level required to experience clinical benefits.

Keywords

Chronic kidney disease Coronary artery disease Gout Hyper uricemia Systemic hypertension Urate-lowering therapy 

Notes

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Oda M, Satta Y, Takenaka O et al (2002) Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640–653CrossRefPubMedGoogle Scholar
  2. 2.
    Kratzer JT, Lanaspa MA, Murphy MN et al (2014) Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A 111:3763–3768CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Johnson RJ, Titte S, Cade JR et al (2005) Uric acid, evolution and primitive cultures. Semin Nephrol 2005(25):3–8CrossRefGoogle Scholar
  4. 4.
    Watanabe S, Kang DH, Feng L et al (2002) Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40:355–360CrossRefPubMedGoogle Scholar
  5. 5.
    Orowan E (1955) The origin of man. Nature 175:683–684CrossRefPubMedGoogle Scholar
  6. 6.
    Alonso A, Rodriguez LA, Logroscino G et al (2007) Gout and risk of Parkinson disease: a prospective study. Neurology 69:1696–1700CrossRefPubMedGoogle Scholar
  7. 7.
    Shen C, Guo Y, Luo W et al (2013) Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci 40:73–79CrossRefPubMedGoogle Scholar
  8. 8.
    Euser SM, Hofman A, Westendorp RG et al (2009) Serum uric acid and cognitive function and dementia. Brain 132(Pt 2):377–382 2009PubMedGoogle Scholar
  9. 9.
    Lu N, Dubreuil M, Zhang Y et al (2016) Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 75:547–551CrossRefPubMedGoogle Scholar
  10. 10.
    Guerrero AL, Gutierrez F, Iglesias F et al (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32:347–350CrossRefPubMedGoogle Scholar
  11. 11.
    Moccia M, Lanzillo R, Costabile T et al (2015) Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol 262:961–967CrossRefPubMedGoogle Scholar
  12. 12.
    Auinger P, Kieburtz K, McDermott MP (2010) The relationship between uric acid levels and Huntington’s disease progression. Mol Disord 25:224–228CrossRefGoogle Scholar
  13. 13.
    Hershfield MS, Roberts LJ 2nd, Ganson NJ et al (2010) Treating gout with pegloticase, a PEGylatedurate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci USA 107:14351–14356CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Corry DB, Eslami P, Yamamoto K et al (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275CrossRefPubMedGoogle Scholar
  15. 15.
    Kang DH, Han L, Ouyang X et al (2005) Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol 25:425–433CrossRefPubMedGoogle Scholar
  16. 16.
    Kang DH, Nakagawa T, Feng L et al (2002) A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13:2888–2897CrossRefPubMedGoogle Scholar
  17. 17.
    Prasad Sah OS, Qing YX (2015) Associations between hyperuricemia and chronic kidney disease: a review. Nephrourol Mon 7(3):e27233CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pillinger MH, Goldfarb DS, Keenan RT (2010) Gout and its comorbidities. Bull NYU Hosp Jt Dis. 68:199–203PubMedGoogle Scholar
  19. 19.
    Goicoechea M, de Vinuesa SG, Verdalles U et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388–1393CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dehghan A, van Hoek M, Sijbrands EJ et al (2008) High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 31:361–362CrossRefPubMedGoogle Scholar
  21. 21.
    Krishnan E, Pandya BJ, Chung L et al (2012) Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: a 15-year follow-up study. Am J Epidemiol 176(2):108–116CrossRefPubMedGoogle Scholar
  22. 22.
    Yoo TW, Sung KC, Shin HS et al (2005) Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 69(8):928–933CrossRefPubMedGoogle Scholar
  23. 23.
    Campion EW, Glynn RJ, Delabry LO (1987) Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 82:421–426CrossRefPubMedGoogle Scholar
  24. 24.
    Langford HG, Blaufox MD, Borhani NO et al (1987) Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 147:645–649CrossRefPubMedGoogle Scholar
  25. 25.
    Lin KC, Lin HY, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501PubMedGoogle Scholar
  26. 26.
    Choi HK, Atkinson K, Karlson EW et al (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277CrossRefPubMedGoogle Scholar
  27. 27.
    Choi HK, Atkinson K, Karlson EW et al (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093CrossRefPubMedGoogle Scholar
  28. 28.
    Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men (2005) the health professionals follow-up study. Arch Intern Med 165:742CrossRefPubMedGoogle Scholar
  29. 29.
    Yu T, Gutman AB (1967) Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 67:1133–1148CrossRefPubMedGoogle Scholar
  30. 30.
    Fessel JW (1979) Renal outcomes of gout and hyperuricemia. Am J Med 67:74–82CrossRefPubMedGoogle Scholar
  31. 31.
    Dincer HE, Dincer AP, Levinson DJ (2002) Asymptomatic hyperuricemia: treat or not to treat. Cleveland clinic J Med 69(8):594–608CrossRefGoogle Scholar
  32. 32.
    Lu CC, Wu SK, Chung WS, Lin LH, Hung TW, Yeh CJ et al (2017) Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout. Clinical Rheumatol 36(8):1903–1909Google Scholar
  33. 33.
    Wang J, Qin T, Chen J, Li Y, Wang L, Huang H et al (2014) Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoSONE 9(12):e114259.  https://doi.org/10.1371/ journal. pone.0114259 CrossRefGoogle Scholar
  34. 34.
    Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(1):102–110CrossRefGoogle Scholar
  35. 35.
    Perlstein TS, Gumieniak O, Williams GH et al (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48:1031–1036CrossRefPubMedGoogle Scholar
  36. 36.
    Mellen PB, Bleyer AJ, Erlinger TP et al (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48:1037–1042CrossRefPubMedGoogle Scholar
  37. 37.
    Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303CrossRefPubMedGoogle Scholar
  38. 38.
    Forman JP, Choi H, Curhan GC (2009) Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 169:155–162CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Leite MA (2011) Uric acid and fibrinogen: age-modulated relationships with blood pressure components. J Human Hypertens 25:476–483CrossRefGoogle Scholar
  40. 40.
    Grayson PC, Kim SY, Lavalley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110CrossRefGoogle Scholar
  41. 41.
    Silverstein D, Srivaths PR, Mattison P et al (2011) Serum uric acid is associated with high blood pressure in pediatric hemodialysis patients. Pediatr Nephrol 26:1123–1128CrossRefPubMedGoogle Scholar
  42. 42.
    Loeffler LF, Navas-Acien A, Brady TM et al (2012) Uric acid level and elevated blood pressure in US adolescents. Hypertension 59:811–817CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Gaffo AL (2013) Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis 72(8):1321–1327.  https://doi.org/10.1136/annrheumdis-2012-201916 CrossRefPubMedGoogle Scholar
  44. 44.
    Kuwabara M, Niwa K, Nishi Y et al (2014) Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res 37:785–789. PubMed CrossRefPubMedGoogle Scholar
  45. 45.
    Cui LF, Shi HJ, Wu SL et al (2017) Association of serum uric acid and risk of hypertension in adults: a prospective study of Kailuan Corporation cohort. Clin Rheum 36(5):1103–1110CrossRefGoogle Scholar
  46. 46.
    Kuwubara M, Niwa K, Hisatone I et al (2017) Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases—Five-Year Japanese Cohort Study. Hypertension 69:1036–1044CrossRefGoogle Scholar
  47. 47.
    Sundstrom J, Sullivan L, D’Agostino RB et al (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45:28–33CrossRefPubMedGoogle Scholar
  48. 48.
    Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary hypertension. Hypertension 42:247–252CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Soletsky B, Feig DI (2012) Uric acid reduction rectifies pre hypertension in obese adolescents. Hypertension 60:1148–1156CrossRefPubMedGoogle Scholar
  51. 51.
    Beattie CJ, Fulton RL, Higgins P (2014) Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 64:1102–1107CrossRefPubMedGoogle Scholar
  52. 52.
    Nakanishi N, Okamato M, Yoshida H et al (2003) Serum uric acid and the risk of developing hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 18:523–530CrossRefPubMedGoogle Scholar
  53. 53.
    Baldwin W, McRae S, Marek G et al (2011) Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60:1258–1269CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Feig DI, Nakagawa T, Karumanchi SA et al (2004) Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 66:281–287CrossRefPubMedGoogle Scholar
  55. 55.
    Murray T, Goldberg M (1975) Chronic interstitial nephritis: etiologic factors. Ann Intern Med 82:453–459CrossRefPubMedGoogle Scholar
  56. 56.
    Li L, Yang C, Zhao Y et al (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122.  https://doi.org/10.1186/1471-2369-15-122 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Johnson RJ, Nakgawa T et al (2013) Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28(9):2221–2228CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Tsai C-W, Lin S-Y, Kuo C-C et al (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini review. PLoSONE 12(1):e0170397.  https://doi.org/10.1371/journal.pone0170393 Google Scholar
  59. 59.
    Fessel WJ (1979) Renal outcomes of gout and hyperuricemia. Am J Med 67:74–82CrossRefPubMedGoogle Scholar
  60. 60.
    Obermayr R, Temmi C, Gutjahr G et al (2008) Elevated uric acid increases the risk for kidney disease. J Am SocNephrol 19(12):2407–2413Google Scholar
  61. 61.
    Weiner D, Tighiouart H, Elsayed E, Griffith J, Salem D, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am SocNephrol 19:1204–1211Google Scholar
  62. 62.
    Whelton A, Macdonald PA, Chefo S, Gunawardhana L (2013) Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 125(1):106–114CrossRefPubMedGoogle Scholar
  63. 63.
    Sircar D, Chatterjee S, Wikhom R et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66(6):945–950CrossRefPubMedGoogle Scholar
  64. 64.
    Abbott RD, Brand FN, Kannel WB et al (1988) Gout and coronary artery disease: the Framingham study. J Clin Epidemiol 41(3):237–242CrossRefPubMedGoogle Scholar
  65. 65.
    Reedman DS, Williamson DF, Gunter EW, Byers T (1995) Relation of serum uric acid to mortality and ischemic heart disease: the NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 141:637–644CrossRefGoogle Scholar
  66. 66.
    Culleton BF, Larson MB, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann.Int Med 131:7–13CrossRefPubMedGoogle Scholar
  67. 67.
    Feig DI, Kang D-H, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811–1821CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Kim SY, Guevara JP, Mi Kim K et al (2010) Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62(2):170–180.  https://doi.org/10.1002/acr.20065 Google Scholar
  69. 69.
    Zuo T, Liu X, Jiang L (2016) Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord 16:207.  https://doi.org/10.1186/s12872-016-0379-z CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Kuo CF, Yu KH, See LC et al (2013) Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 52(1):111–117CrossRefGoogle Scholar
  71. 71.
    Palmer TM, Nordestgaard BG, Benn M (2013) Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 347:f4262.  https://doi.org/10.1136/bmj.f4262 CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Capuano V, Marchese F, Capuano R et al (2017) Hyperuricemia as an independent risk factor for major cardiovascular events: a 10-year cohort study from Southern Italy. J Cardiovasc Med 18(3):159–164CrossRefGoogle Scholar
  73. 73.
    Anker SD, Doehner W, Rauchhaus M et al (2003) Uric acid and survival in chronic heart failure. Circulation 107:1991–1199CrossRefPubMedGoogle Scholar
  74. 74.
    Kim H, Seok-hyung K, Choi AR (2017) Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study. Medicine 96(14):e6565.  https://doi.org/10.1097/MD.0000000000006565 CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Becker MA, Jolly M (2006) Hyperuricemia and associated diseases. Rheum Dis Clin N Am 32:275–293CrossRefGoogle Scholar
  76. 76.
    Burns CM, Wortmann RL (2017) Clinical features and treatment of gout. In: Firestein GS, Budd RC, Gabriel SC, McInnes IB, O'Dell JR (eds) Kelley and Firestein’s textbook of rheumatology, 10th edn. Elsevier, Philadelphia, p 1620–1644Google Scholar
  77. 77.
    Richette P, Doherty M, Pascual E et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 78:29–42.  https://doi.org/10.1136/annrheumdis--209707 CrossRefGoogle Scholar
  78. 78.
    Zhang Y, Neogi T, Chen C (2012) Cherry consumption and the risk of recurrent gout attacks. Arthritis Rheum 64(12):4004–4011.  https://doi.org/10.1002/art.34677 CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Park KY, Kim HJ, Ahn HS (2016) Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. Semin Arthritis Rheum 45(5):580–586CrossRefPubMedGoogle Scholar
  80. 80.
    Juraschek SP, Miller ER, Gelber AC (2011) Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 63(9):1295–1306 2011CrossRefGoogle Scholar
  81. 81.
    Qin X, Li Y, He M et al (2017) Folic acid therapy reduces serum uric acid in hypertensive patients: a sub study of the China Stroke Primary Prevention Trial (CSPPT). Am J Clin Nutr 105(4):882–889CrossRefPubMedGoogle Scholar
  82. 82.
    Hosoya T, Sasaki T, Ohashi T (2017) Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clinical Rheumatology 36(3):649–656CrossRefPubMedGoogle Scholar
  83. 83.
    Stamp L, Dalbeth N (2017) Urate lowering therapy for asymptomatic hyperuricemia. A need for caution Sem Arthritis Rheum 46:457–464CrossRefGoogle Scholar
  84. 84.
    Levy G, Cheetham TC (2015) Is it time to start treating asymptomatic hyperuricemia? Am J Kidney Dis 66(6):933–935CrossRefPubMedGoogle Scholar
  85. 85.
    Ramirez MEG, Bargman JM (2017) Treatment of asymptomatic hyperuricemia in chronic kidney disease: a new target in an old enemy—a review. J Adv Res 8(5):551–554CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2017

Authors and Affiliations

  1. 1.Department of Internal MedicineKMCT Medical College ManasseryCalicutIndia

Personalised recommendations